389.46 USD
-5.31
1.35%
At close Jul 11, 4:00 PM EDT
After hours
389.46
+0.00
0.00%
1 day
-1.35%
5 days
-1.21%
1 month
2.20%
3 months
11.19%
6 months
7.89%
Year to date
8.57%
1 year
15.19%
5 years
118.97%
10 years
298.91%
 

About: Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one fourth of Stryker's total revenue currently comes from outside the United States.

Employees: 53,000

0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

73% more first-time investments, than exits

New positions opened: 161 | Existing positions closed: 93

70% more call options, than puts

Call options by funds: $613M | Put options by funds: $360M

28% more repeat investments, than reductions

Existing positions increased: 927 | Existing positions reduced: 726

10% more funds holding in top 10

Funds holding in top 10: 73 [Q4 2024] → 80 (+7) [Q1 2025]

1% more funds holding

Funds holding: 2,150 [Q4 2024] → 2,175 (+25) [Q1 2025]

2% more capital invested

Capital invested by funds: $108B [Q4 2024] → $110B (+$2.49B) [Q1 2025]

0.21% less ownership

Funds ownership: 77.85% [Q4 2024] → 77.64% (-0.21%) [Q1 2025]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$400
3%
upside
Avg. target
$432
11%
upside
High target
$456
17%
upside

4 analyst ratings

positive
75%
neutral
25%
negative
0%
Evercore ISI Group
Vijay Kumar
7%upside
$415
Outperform
Maintained
8 Jul 2025
Citigroup
Joanne Wuensch
17%upside
$455
Buy
Maintained
22 May 2025
Truist Securities
Richard Newitter
3%upside
$400
Hold
Maintained
5 May 2025
Roth MKM
Jason Wittes
17%upside
$456
Buy
Maintained
2 May 2025

Financial journalist opinion

Based on 7 articles about SYK published over the past 30 days

Neutral
Zacks Investment Research
17 hours ago
Smart Money Going in Senior Health: Key Stocks in Elderly Care
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
Smart Money Going in Senior Health: Key Stocks in Elderly Care
Neutral
GlobeNewsWire
23 hours ago
North America Cystoscopes Market Outlook Report 2025-2033 Featuring Key Companies - Olympus, KARL STORZ, Stryker, PENTAX Medical, Richard Wolf, Ambu, Laborie Medical Technologies
Discover comprehensive insights with the "North America Cystoscopes Market Outlook to 2033" report. Analyze market data, company shares, and segment details for Flexible and Rigid Cystoscopes. Develop strategic plans and investment strategies by identifying growth opportunities in the North America Cystoscopes market. Discover comprehensive insights with the "North America Cystoscopes Market Outlook to 2033" report. Analyze market data, company shares, and segment details for Flexible and Rigid Cystoscopes. Develop strategic plans and investment strategies by identifying growth opportunities in the North America Cystoscopes market.
North America Cystoscopes Market Outlook Report 2025-2033 Featuring Key Companies - Olympus, KARL STORZ, Stryker, PENTAX Medical, Richard Wolf, Ambu, Laborie Medical Technologies
Neutral
Zacks Investment Research
4 days ago
HLN vs. SYK: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with Haleon PLC Sponsored ADR (HLN) and Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
HLN vs. SYK: Which Stock Is the Better Value Option?
Neutral
GlobeNewsWire
1 week ago
Stryker to announce financial results for its second quarter of fiscal year 2025
Portage, Michigan, July 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its second quarter of fiscal year 2025 on Thursday, July 31, 2025.  A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's second quarter that ended June 30, 2025.
Stryker to announce financial results for its second quarter of fiscal year 2025
Positive
Zacks Investment Research
1 week ago
SYK Boosts Foot & Ankle Portfolio With FDA-Cleared Total Ankle System
Stryker expands its Foot & Ankle portfolio with FDA-cleared InCompass, targeting streamlined total ankle replacement.
SYK Boosts Foot & Ankle Portfolio With FDA-Cleared Total Ankle System
Positive
Schwab Network
2 weeks ago
The Big 3: NXT, ANET, SYK
Today's trading action added confidence to Dan Deming's perception on the markets, noting widening market breadth as a healthy sign for price action. On individual stocks, he sees growth opportunities in Nextracker (NXT) amid volatility, Arista Networks (ANET) gaining momentum as the stock remains off highs, and Stryker (SYK) holding strength in healthcare tech.
The Big 3: NXT, ANET, SYK
Neutral
Business Wire
2 weeks ago
Stryker receives FDA clearance for Incompass Total Ankle System
PORTAGE, Mich.--(BUSINESS WIRE)--Stryker received FDA 510(k) clearance for its Incompass® Total Ankle System, intended for patients with severe arthritis-related ankle joint damage.
Stryker receives FDA clearance for Incompass Total Ankle System
Positive
The Motley Fool
1 month ago
5 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Volatility is a part of life for long-term investors. The reasons the market goes up or down change, but the constant is that high-quality stocks, businesses that increasingly make more money over time, will reward investors if you wait long enough.
5 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Negative
Morningstar
1 month ago
The 3 Most Overvalued Stocks Top Managers Are Selling in 2025
The best fund managers are scaling back in these expensive stocks this year. 00:00 Introduction 00:39 Netflix NFLX 01:23 Mastercard MA 02:07 Stryker SYK Susan Dziubinski: I'm Susan Dziubinski with Morningstar.
The 3 Most Overvalued Stocks Top Managers Are Selling in 2025
Positive
Zacks Investment Research
1 month ago
PBH vs. SYK: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks is more attractive to value investors?
PBH vs. SYK: Which Stock Is the Better Value Option?
Charts implemented using Lightweight Charts™